Glenmark Pharma gains after JV submits IND application for cancer drug ISB 2301
Ichnos Glenmark Innovation plans to initiate a Phase I clinical trial of ISB 2301 in patients with solid tumours in 2027.
Lida Pacaud, M.D., president and chief executive officer, IGI, said, ?ubmission of the IND for ISB 2301 marks an important milestone in advancing IGI?s multispecific oncology pipeline into clinical development, this pentaspecific candidate is designed to integrate multiple tumortargeting and immune-engaging functions within a single molecule. Our preclinical results have demonstrated a compelling anti-cancer profile for ISB 2301, a candidate we believe to be highly differentiated from current approaches. We plan to initiate a Phase 1 clinical trial of ISB 2301 in patients with solid tumors in 2027.?
Glenmark Pharmaceuticals manufactures pharmaceutical formulations and active pharmaceutical ingredients, which it markets in India and abroad. It also undertakes R&D on new chemical and biological entities. The company has 10 manufacturing facilities spread across India, USA and a few other countries.
The company?s consolidated net profit declined 56.78% YoY to Rs 263.78 core in Q2 FY27. Net sales dropped 29.76% to Rs 4,247.33 crore in Q2 FY27 compared with Rs 6,046.87 crore in Q2 FY26.
Powered by Capital Market - Live News